Value202020212022202320242025TTMSelling/general/admin expenses———144.5 M155.78 M165.41 M165.41 MResearch & development———163.54 M222.15 M274.87 M274.87 MOperating income———59.65 M70.46 M45.35 M45.35 MNon-Operating Income, Total———32.06 M43.26 M38.42 M38.42 MInterest expense, net of interest capitalized———5.15 M18.84 M12.17 M12.17 MNon-Operating Income, excl. Interest Expenses———26.01 M10.22 M6.53 M6.53 MUnusual income/expense———897 K14.2 M19.73 M19.73 MPretax income———60.89 M52.94 M19.1 M19.1 MEquity in earnings———————Taxes———5.6 M1.85 M16.41 M16.41 MNon-controlling/minority interest———————After tax other income/expense———412 K1.84 M2.11 M2.11 MNet income before discontinued operations———55.29 M51.09 M35.51 M35.51 MDiscontinued operations———————Net income———55.29 M51.09 M35.51 M35.51 MDilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders———55.29 M51.09 M35.51 M35.51 MBasic earnings per share (Basic EPS)———-1.13-1.02-0.71-0.71Diluted earnings per share (Diluted EPS)———-1.13-1.02-0.71-0.71Average basic shares outstanding———48.89 M49.99 M50.35 M201.13 MDiluted shares outstanding———48.89 M49.99 M50.35 M202.99 MEBITDA———-55.55 M-66.26 M-42.25 M-42.09 MEBIT———-59.65 M-70.46 M-45.35 M-45.35 MCost of revenue———1.04 M2.73 M5.09 M5.09 MOther cost of goods sold———————Depreciation & amortization (cash flow)———4.1 M4.2 M3.1 M3.27 M
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.